Xinzheng Dai

Xinzheng Dai


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
LZLiren Zhang
Liren Zhang
JXJiali Xu
Jiali Xu
SZSuiqing Zhou
Suiqing Zhou
FYFeifan Yao
Feifan Yao
RZRuizhi Zhang
Ruizhi Zhang
XWxuehao wang
xuehao wang

3 May 2024 in Cancer Letters
Verified
Journal Article
Closed access
FYFeifan Yao
Feifan Yao
SZSuiqing Zhou
Suiqing Zhou
RZRuizhi Zhang
Ruizhi Zhang
YCYining Chen
Yining Chen
WHWei Huang
Wei Huang
QLQing Li
Qing Li

28 August 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LYLei Yue
Lei Yue
XXXiaozhang Xu
Xiaozhang Xu
SDShipeng Dai
Shipeng Dai
FXFan Xu
Fan Xu
WZWenhu Zhao
Wenhu Zhao
XQXiaofeng Qian
Xiaofeng Qian
Approximately 25–30% of those affected by colorectal cancer (CRC), the most prevalent gastrointestinal malignancy, develop metastases. The survival rate of patients with liver metastasis of CRC (CRLM) remains low owing to its unpredictability and a lack of biomarkers that can be applied to distinguish groups at higher risk for CRLM among patients with CRC. Therefore, our study aimed to find biomarkers that can predict the risk of CRLM. Screening of the Gene Expression Omnibus database, supported by an analysis of clinically obtained tissue and serum data using qPCR and ELISA, in an attempt to identify relevant biomarkers, enabled us to determine that orosomucoid 1 (ORM1) was differentially expressed in liver metastases and primary tumors of patients with CRC. Functionally, overexpression of ORM1 promoted the epithelial-mesenchymal transition and the proliferative, migratory, and invasive activities of MC38 cells and activated the PI3K/AKT signaling pathway. Moreover, MC38 cells overexpressing ORM1 enhanced the tumor immune microenvironment by promoting macrophage M2 polarization and elevating interleukin-10 (IL-10) expression. In vivo experiments further confirmed in vitro results, indicating that liver metastases elevated by ORM1 were partially attenuated by the depletion of macrophages or IL-10. Considered together, ORM1 promotes CRC progression and liver metastasis by regulating tumor cell growth and inducing macrophage M2 polarization, which mediates tumor immune tolerance, and thus acts as a potential predictive marker and therapeutic target in CRLM.

25 February 2019 in APMIS
Verified
Journal Article
Closed access
PDF file
YSYu Sun
Yu Sun
JGJian Gu
Jian Gu
RLRui Liu
Rui Liu
HZHaoming Zhou
Haoming Zhou
LLLing Lu
Ling Lu
XQXiaofeng Qian
Xiaofeng Qian

28 November 2023 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
JDJingjing Dai
Jingjing Dai
LZLiren Zhang
Liren Zhang
RZRuizhi Zhang
Ruizhi Zhang
JGJing Ge
Jing Ge
FYFeifan Yao
Feifan Yao
QLQing Li
Qing Li
Metabolic dysfunction-associated steatohepatitis (MASH) is a common chronic liver disease worldwide. No effective pharmacological therapies for MASH have been developed; to develop such promising drugs, the underlying mechanisms regulating MASH need to be elucidated. Here, we aimed to determine the role of OTUD5 in MASH progression and identify a specific mechanism. The expression levels of OTUD subfamily under palmitic acid/oleic acid (PAOA) stimulation were screened. OTUD5 expression was assessed in human liver tissues without steatosis, those with simple steatosis, and those with MASH. MASH models were developed in hepatocyte-specific Otud5-knockout mice that were fed high-fat high-cholesterol (HFHC) and high-fat high-cholesterol plus high-fructose/sucrose (HFF) diet for 16 weeks. The expression of OTUD5 was downregulated in fatty liver and was negatively related to the progression of MASH. Lipid accumulation and inflammation were exacerbated by Otud5 knockdown but attenuated by Otud5 overexpression under PAOA treatment. Hepatocyte-specific Otud5 deletion markedly exacerbated steatosis, inflammation, and fibrosis in the livers of two MASH mouse models. We identified voltage-dependent anion channel 2 (VDAC2) as an OTUD5-interacting partner; OTUD5 cleaved the K48-linked polyubiquitin chains from VDAC2, and it inhibited subsequent proteasomal degradation. The anabolic effects of OTUD5 knockdown on PAOA-induced lipid accumulation were effectively reversed by VDAC2 overexpression in primary hepatocytes. Metabolomic results revealed that VDAC2 is required for OTUD5-mediated protection against hepatic steatosis by maintaining mitochondrial function. OTUD5 may ameliorate MASH progression via VDAC2-maintained mitochondrial homeostasis. Targeting OTUD5 may be a viable MASH-treatment strategy.

1 August 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
HZHaoming Zhou
Haoming Zhou
YSYu Sun
Yu Sun
QWQingyuan Wang
Qingyuan Wang
ZLZhi Li
Zhi Li
WZWeizhe Zhong
Weizhe Zhong
LKLianbao Kong
Lianbao Kong